Zimmer Biomet Holdings (XSWX:ZBH) Asset Impairment Charge: CHF0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:ZBH Zimmer Biomet Holdings Inc XSWX:ZBH
77 GF Score
Price CHF77.50
GF Value CHF101.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Asset Impairment Charge?

Zimmer Biomet Holdings XSWX:ZBH +2.65% 77 Asset Impairment Charge is CHF0 Mil as of Jun. 2026. GuruFocus rates XSWX:ZBH with a GF Score™ of 77/100 and a GF Value™ of CHF101.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Zimmer Biomet Holdings's Asset Impairment Charge for the three months ended in Jun. 2026 was CHF0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was CHF0 Mil.

Zimmer Biomet Holdings Asset Impairment Charge Related Terms

Zimmer Biomet Holdings Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Asset Impairment Charge Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zimmer Biomet Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:ZBH
77GF Score
Zimmer Biomet Holdings Inc XSWX:ZBH
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zimmer Biomet Holdings Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0 Mil.

What does a Asset Impairment Charge of CHF0 Mil mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a Asset Impairment Charge of CHF0 Mil as of Jun. 2026.
Is Zimmer Biomet Holdings' Asset Impairment Charge too high?
Zimmer Biomet Holdings' current Asset Impairment Charge is CHF0 Mil. Overall, Zimmer Biomet Holdings has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Asset Impairment Charge compare to STE and PEN?
Zimmer Biomet Holdings' Asset Impairment Charge of CHF0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Medical Devices & Instruments company?
A good Asset Impairment Charge depends on the Medical Devices & Instruments industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Zimmer Biomet Holdings's current Asset Impairment Charge is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF101.61, compared to a current price of CHF77.50 — trading 23.7% below its estimated fair value. The current Asset Impairment Charge is CHF0 Mil. Zimmer Biomet Holdings' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Asset Impairment Charge is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of CHF77.50 is trading 23.7% below its estimated GF Value™ of CHF101.61. GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.

Key valuation signals for XSWX:ZBH:

  • Asset Impairment Charge: CHF0 Mil
  • GF Value™: CHF101.61 vs. price of CHF77.50 (23.7% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
77GF Score

Get the complete analysis for XSWX:ZBH

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF77.50
Price
CHF101.61
GF Value